{"brief_title": "Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke", "brief_summary": "This study will determine if NXY-059 will improve recovery from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strengthen and coordination.", "condition": ["Cerebral Stroke", "Stroke, Acute", "Cerebrovascular Stroke", "Ischemic Attack, Transient"], "intervention_type": ["Drug"], "intervention_name": ["NXY-059"], "criteria": "Inclusion Criteria: - Males and females - Acute ischemic stroke with limb weakness - Onset of symptoms within 6 hours - Full functional independence prior to the present stroke Exclusion Criteria: - Unconsciousness - Subjects who are unlikely to complete the infusion of investigational product and/or are unlikely to undergo active medical management during that period due to a severe clinical condition. - Severe illness with life expectancy less than 6 months. - Known severe kidney disorder. - Current known alcohol or illicit drug abuse or dependence. - Pregnant or breast-feeding. - Treatment with acetazolamide and methotrexate is not permitted during the infusion - Participation in a previous clinical study within 30 days. - Meets all other exclusion criteria.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Cataplexy", "mesh_term": ["Stroke", "Ischemia", "Ischemic Attack, Transient", "Disufenton sodium"], "id": "NCT00061022"}